Evolution in the Field of HR+ Breast Cancer Management
Closing out their discussion on HR+ breast cancer management, expert panelists share their excitement for the evolving treatment paradigm.
Other Treatment Modalities for HR+ Metastatic Breast Cancer
Comprehensive discussion on novel treatment modalities in HR+ metastatic breast cancer and insight to when it is appropriate to select these agents.
HR+ Metastatic Breast Cancer: Optimal Selection of Endocrine Partners
Shared insight on the selection of endocrine partners while managing patients in the relapsed/refractory setting of HR+ metastatic breast cancer.
Advice for Community Physicians on Managing HER2+ Breast Cancer
Closing out their review on treatment strategies for HER2-expressing breast cancer, panelists share practical advice for the community setting.
Continuing CDK4/6 Inhibition at Progression of HR+ Metastatic Breast Cancer
Key opinion leaders consider when it is appropriate to continue CDK4/6 inhibition at progression of disease in the setting of HR+ metastatic breast cancer.
Molecular Testing in Relapsed/Refractory HR+ Metastatic Breast Cancer
A brief review of the role molecular profiling plays at a patient’s relapse with HR+ metastatic breast cancer.
Potential Role for T-DXd in Early-Stage HER2-Low Breast Cancer
Panelists share a brief discussion on early-stage HER2-low breast cancer and identify treatment options available in that setting.
Optimizing Real-World Management of HER2-Low Breast Cancer
Comprehensive insight on evolving management strategies for patients diagnosed with HER2-low breast cancer.
Dr. McArthur on the Implications of the ASCENT Trial in TNBC
Heather Lynn McArthur, MD, MPH, discusses the implications of the phase 3 ASCENT trial in patients with advanced triple-negative breast cancer.
Factors in Selecting 1L Therapy for Patients With HR+ Metastatic Breast Cancer
Expert perspectives on factors that aid in the selection of optimal first-line therapy for patients with HR+ metastatic breast cancer.
HR+ Metastatic Breast Cancer: Molecular Profiling and 1L Treatment Approaches
Shifting their focus to HR+ metastatic disease, expert panelists consider the importance of molecular profiling and first-line treatment options.
Expert Perspectives on Defining HER2-Low Breast Cancer
Centered discussion on the advent of HER2-low breast cancer and how it is differentiated from HER2+ and HER2- disease.
Overview on Treatment Options for HER2+ Breast Cancer
Expert panelists provide a broad overview on HER2+ breast cancer and review the evolving treatment armamentarium.
How Clinical Trials Inform Treatment Selection in Early-Stage HR+ Breast Cancer
A brief review of prevalent clinical trials in the early-stage HR+ breast cancer paradigm and how they help to inform treatment decision-making.
Early-Stage HR+ Breast Cancer: Ki67 and the monarchE Trial
Key opinion leaders in breast cancer management discuss Ki67 and the monarchE trial, which analyzed abemaciclib therapy in the HR+ space.
How Ki67 Informs Use of Therapy in Early-Stage HR+ Breast Cancer
A broad look at the role of Ki67 expression in informing the selection of therapy for patients with early-stage HR+ breast cancer.
Best Practices for Molecular Testing in Early-Stage Breast Cancer
Expert panelists share their perspectives on best practices for molecular profiling in patients diagnosed with early-stage breast cancer.
Dr. McArthur on the FDA Approval of Second-Line Trastuzumab Deruxtecan in HER2+ Breast Cancer
Heather McArthur, MD, MPH, discusses the FDA approval of fam-trastuzumab deruxtecan-nxki for second-line treatment in HER2-positive metastatic breast cancer.
SABCS 2021: Novel Approaches to Breast Cancer Management
After discussing a few more key datasets from the SABCS 2021 Virtual Meeting, expert panelists discuss how they would approach treatment in several subsets of breast cancer.
SABCS 2021: Brain Metastases Updates in Breast Cancer
Focusing on datasets from the SABCS 2021 Virtual Meeting, panelists consider novel approaches to the management of brain metastases in breast cancer.
SABCS 2021: Updates in Metastatic Breast Cancer
Expert panelists share their perspectives on metastatic breast cancer management datasets from the SABCS 2021 Virtual Meeting.
Further Understanding of Immune Mechanisms in Tumor Microenvironment Is Key to Advancing Immunotherapy in Solid Tumors
Navigating Systemic Therapy for RCC: Balancing Risk Status and Response
ADCs, Novel Targets Represent Next Wave of Treatment Advances in mCRPC
Precision Medicine in Prostate Cancer Care: Keeping Up With Evolving Guidance for Testing and Decision Making
2 Clarke Drive Cranbury, NJ 08512